SCHEMBL106734

SCHEMBL106734

CCOC(=O)c1occc1-c1ccc(N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 6/20 0.53
LMNA P02545 3/20 0.53
CYP1A2 P05177 3/20 0.53
CYP3A4 P08684 2/20 0.53
MAOA P21397 1/20 0.53
ALDH1A1 P00352 6/20 0.47
HSD17B10 Q99714 4/20 0.47
NPC1 O15118 4/20 0.47
MAPT P10636 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 2/20 0.47
ALOX15 P16050 2/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
KDM4E B2RXH2 4/20 0.43
AHR P35869 1/20 0.43
JAK2 O60674 1/20 0.41
JAK3 P52333 1/20 0.41
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975204 0.87 CA12 (0.51) PRKCZCYP1A2ALDH1A1NPC1MAPT
SCHEMBL26559455 0.87 PRKCZ (0.52) PRKCZLMNAALDH1A1NPC1MAPT
SCHEMBL12951698 0.85 MAPT (0.42) PRKCZCYP1A2ALDH1A1HSD17B10NPC1
SCHEMBL3982536 0.85 TSHR (0.47) LMNACYP1A2CYP3A4ALDH1A1HSD17B10
SCHEMBL12951573 0.84 MAPT (0.44) PRKCZLMNACYP1A2CYP3A4MAOA
SCHEMBL12483581 0.83 CA1 (0.54) MEN1KMT2A
SCHEMBL3976847 0.83 SMN1; SMN2 (0.53) LMNACYP1A2CYP3A4MAOAALDH1A1
SCHEMBL12951704 0.83 CYP4F2 (0.45) PRKCZCYP1A2ALDH1A1HSD17B10NPC1
SCHEMBL1255948 0.82 ALDH1A1 (0.52) ALDH1A1HSD17B10HPGDMAPK1
SCHEMBL16882126 0.80 RAB9A (0.38) PRKCZCYP1A2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459215-B 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmacy acceptable salt thereof DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) 2016-03-02 CN disclosed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
CN-102459215-A 3- (4-aminophenyl) -2-furancarboxylic acid derivatives and pharmaceutically acceptable salts thereof DAINIPPON SUMITOMO PHARMA CO 2012-05-16 CN disclosed
EP-2431362-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-03-21 EP disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
WO-2010131669-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 大日本住友製薬株式会社 (JP) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACSL3, SLCO4C1, SLC38A7 PRKCZ 3618/4885LMNA 3481/4885CYP1A2 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.